SCHEMBL6730620

SCHEMBL6730620

OCc1ccc(NCc2cccnc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.70
ALDH1A1 P00352 3/20 0.69
MAPT P10636 2/20 0.59
MEN1 O00255 1/20 0.59
PABPC1 P11940 1/20 0.59
KMT2A Q03164 1/20 0.59
CYP1A2 P05177 7/20 0.55
CYP2D6 P10635 6/20 0.55
KDM4E B2RXH2 1/20 0.54
GAA P10253 1/20 0.54
MKNK1 Q9BUB5 1/20 0.53
MKNK2 Q9HBH9 1/20 0.53
RAB9A P51151 1/20 0.51
CYP3A4 P08684 6/20 0.51
CYP2C9 P11712 6/20 0.51
CYP2C19 P33261 6/20 0.51
CCNE1 P24864 1/20 0.51
CDK2 P24941 1/20 0.51
POLB P06746 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6730573 0.85 LTA4H (0.72) LTA4HALDH1A1MAPTMEN1PABPC1
SCHEMBL13766317 0.83 ALDH1A1 (0.73) LTA4HALDH1A1MAPTMEN1PABPC1
SCHEMBL6730389 0.83 LTA4H (0.81) LTA4HALDH1A1MAPTMEN1PABPC1
SCHEMBL27691890 0.83 LTA4H (0.70) LTA4HALDH1A1MAPTMEN1PABPC1
SCHEMBL30642394 0.82 LTA4H (1.00) LTA4HALDH1A1MAPTMEN1PABPC1
SCHEMBL523753 0.82 LTA4H (1.00) LTA4HALDH1A1MAPTMEN1PABPC1
SCHEMBL2636199 0.81 LTA4H (0.67) LTA4HALDH1A1MAPTMEN1PABPC1
SCHEMBL6730610 0.81 LTA4H (0.72) LTA4HALDH1A1MAPTMEN1PABPC1
SCHEMBL171745 0.81 ALDH1A1 (1.00) LTA4HALDH1A1MAPTMEN1PABPC1
SCHEMBL6710546 0.81 LTA4H (0.72) LTA4HALDH1A1MAPTMEN1PABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114007696-A Compounds for treating oncovirus-induced cancer and methods of use thereof 塞莱斯蒂亚生物技术股份公司 2022-02-01 CN disclosed
US-6800651-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-10-05 US disclosed
US-20040006114-A1 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-01-08 US disclosed
EP-1255735-A2 PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2002-11-13 EP disclosed
WO-2001056990-A2 PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006114-A1 Potentiators of glutamate receptors GRM1, GRIN1, GRM2 LTA4H 1721/4885ALDH1A1 1187/4885MAPT 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.